MARKETING ANALYSIS OF THE COST OF COUNTERFEIT MEDICINES IN THE PHARMACEUTICAL MARKET OF RUSSIA

Abstract

The presence of counterfeit pharmaceutical products is one of the threats to the development of the pharmaceutical market in Russia. The reasons for the introduction of drugs of inadequate quality (substandard, falsified and counterfeit) are the high cost of original drugs, the imperfection of the legislative framework, high tariffs for the release of drugs to the market and others.

Full Text

Relevance. The presence of counterfeit pharmaceutical products is one of the threats to the development of the pharmaceutical market in Russia. The reasons for the introduction of drugs of inadequate quality (substandard, falsified and counterfeit) are the high cost of original drugs, the imperfection of the legislative framework, high tariffs for the release of drugs to the market and others.
The purpose of the study: marketing analysis of the cost of counterfeit drugs identified in the pharmaceutical market of Russia in 2021.
Research methods: logical, comparative, content analysis.
Research materials: informational letters of the Federal Service for Supervision of Healthcare of the Russian Federation for 2021, official websites of online pharmacies of the country (Apteka.ru ; Zdravcity; SberApteka; April).
The results of the study. In 2021, 11 trade names of counterfeit medicines (LP) were identified in the pharmaceutical market of Russia, the cost of which varies from 1,646.50 rubles. (Essentiale ® N) up to 124879.00 rubles. (Kadsila).
Thus, the group of counterfeit products does not include LP of a low price category. Due to the high amplitude of prices during the logical analysis, three groups of LP were identified by cost: medium price category (up to 8000 rubles), high (from 8000 to 16000 rubles) and very high (over 16000 rubles) (Table 1).

Table 1 - Price groups of counterfeit LP

Price segment	Trade name	Pharmacotherapeutic group	Average price for 1 package, rub.
Middle price segment	Essentiale ® N	Hepatoprotective agent	1646,50
	Seroquel XR	Antipsychotic (neuroleptic) agent	2898,50
	Xarelto ® , 20 mg Xarelto ® , 2.5 mg Xarelto ® , 15 mg	Direct Factor Xa inhibitors	3064,50 3737,50 3120,00
	Adenuric ®	Anti-gouty agent, xanthine oxidase inhibitor	3172,00
High price segment	Prolia ®	Drugs for the treatment of bone diseases are other drugs that affect the structure and mineralization of bone.	13330,25
	Aklasta	Bone resorption inhibitor - bisphosphonate	15064,75
	Mirena ®	Gestagen	15236,67
Very high price segment	Phazlodex	Antitumor agent, antiestrogen	36696,00
	Simzia ®	MIBP-monoclonal antibodies	55864,00
	Kadsila	Antitumor agent - monoclonal antibodies	124879,00
No information available	Nexium	Proton Pump inhibitor	-

The analysis showed that the group of counterfeit drugs withdrawn from circulation in the pharmaceutical market of Russia in 2021 is represented by expensive hepatoprotective, neuroleptic, antithrombic, anti-gouty, monoclonal antibodies, correctors of bone and cartilage tissue metabolism, progestogens, antitumor drugs and proton pump inhibitors. Considering that the main reasons for the seizure are violation of civil legislation and labeling in Turkish or Ukrainian, it can be concluded that the directed production and import of counterfeit LP of a high price category.